Trump announces trade deal with EU following months of negotiations
NEW YORK - Revvity, Inc. (NYSE:RVTY) shares jumped 5.25% in after-hours trading on Friday after the health science solutions provider reported fourth-quarter earnings that beat analyst expectations.
The company posted adjusted earnings per share of $1.42 for the quarter, surpassing the consensus estimate of $1.37. Revenue came in at $729 million, slightly below analysts’ projections of $731.15 million but up 5% YoY.
Revvity’s fourth-quarter organic revenue growth was 6%, driven by a 6% increase in its Diagnostics segment and 5% growth in Life Sciences.
"We finished last year on a strong note positioning us well as we head into 2025," said Prahlad Singh, president and CEO of Revvity.
For the full year 2025, Revvity forecasts revenue of $2.80-$2.85 billion and adjusted EPS of $4.90-$5.00. The revenue guidance midpoint of $2.825 billion falls short of the $2.863 billion consensus estimate.
The company’s adjusted operating margin expanded to 30.3% in Q4 from 27.5% a year ago, reflecting improved profitability.
Revvity ended 2024 with $1.16 billion in cash and cash equivalents on its balance sheet.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.